Black M H, Magklara A, Obiezu C, Levesque M A, Sutherland D J, Tindall D J, Young C Y, Sauter E R, Diamandis E P
Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada.
Br J Cancer. 2000 Jan;82(2):361-7. doi: 10.1054/bjoc.1999.0927.
The recent demonstration of human glandular kallikrein (hK2) expression in a breast carcinoma cell line has suggested that this putatively prostate-restricted, steroid hormone-regulated protease may also be expressed in breast epithelium in vivo and secreted into the mammary duct system. Given that the only substrate yet identified for hK2 activity is the precursor of prostate-specific antigen (PSA), the expression of which in breast carcinomas may be associated with favourable prognosis, our purpose was to examine the expression pattern of both hK2 and PSA in breast tumour tissues. Cytosolic extracts of 336 primary breast carcinomas prepared for routine oestrogen receptor (ER) and progesterone receptor (PR) analysis, as well as 31 nipple aspirates from six women with non-diseased mammary glands, were assayed for hK2 and PSA using immunofluorometric assays developed by the authors. In the tumour extracts, measurable hK2 and PSA concentrations were detected in 53% and 73% of cases respectively, and were positively correlated to each other (r = 0.59, P = 0.0001). Higher concentrations of PSA and hK2 were found in tumours expressing steroid hormone receptors (P = 0.0001 for PSA and P = 0.0001 for hK2, by Wilcoxon tests for both ER and PR), and both PSA (r = 0.25, P = 0.0001) and hK2 (r = 0.22, P = 0.0001) correlated directly with PR levels. A negative correlation between patient age and PSA (r = -0.12, P = 0.03) was also found. Both proteins were present in nipple aspirate fluid at relatively high concentrations which were positively correlated (r = 0.53, P = 0.002). The molecular weights of the immunoreactive species quantified by the hK2 and PSA assays were established by high-performance liquid chromatography (HPLC) and were consistent with the known molecular weights of hK2 and PSA. Together these data provide the first evidence, to our knowledge, that both malignant breast tissue and normal breast secretion contain measurable quantities of hK2, and that the degree of hK2 expression or secretion is directly proportional to the expression of PSA and steroid hormone receptors. hK2 expression may therefore be a marker of steroid hormone action in breast tissue.
最近在一种乳腺癌细胞系中证实了人腺激肽释放酶(hK2)的表达,这表明这种被认为受前列腺限制、受类固醇激素调节的蛋白酶在体内乳腺上皮中也可能表达,并分泌到乳腺导管系统中。鉴于目前已确定的hK2活性的唯一底物是前列腺特异性抗原(PSA)的前体,而PSA在乳腺癌中的表达可能与良好预后相关,我们的目的是研究hK2和PSA在乳腺肿瘤组织中的表达模式。使用作者开发的免疫荧光测定法,对336例为常规雌激素受体(ER)和孕激素受体(PR)分析准备的原发性乳腺癌的细胞溶质提取物,以及6名乳腺无病变女性的31份乳头抽吸液进行了hK2和PSA检测。在肿瘤提取物中,分别在53%和73%的病例中检测到可测量的hK2和PSA浓度,且二者呈正相关(r = 0.59,P = 0.0001)。在表达类固醇激素受体的肿瘤中发现PSA和hK2浓度较高(通过对ER和PR的Wilcoxon检验,PSA的P = 0.0001,hK2的P = 0.0001),且PSA(r = 0.25,P = 0.0001)和hK2(r = 0.22,P = 0.0001)均与PR水平直接相关。还发现患者年龄与PSA呈负相关(r = -0.12,P = 0.03)。两种蛋白在乳头抽吸液中的浓度相对较高,且呈正相关(r = 0.53,P = 0.002)。通过高效液相色谱(HPLC)确定了hK2和PSA测定法定量的免疫反应性物质的分子量,其与hK2和PSA的已知分子量一致。据我们所知,这些数据共同首次表明,恶性乳腺组织和正常乳腺分泌物中均含有可测量的hK2,且hK2的表达或分泌程度与PSA和类固醇激素受体的表达直接成正比。因此,hK2表达可能是乳腺组织中类固醇激素作用的一个标志物。